Britain picks Glaxo's Cervarix for vaccine program
LONDON, June 18
LONDON, June 18 (Reuters) - GlaxoSmithKline's (GSK.L) cervical cancer vaccine Cervarix was picked as the medicine of choice for the British Department of Health's immunisation program, the drugmaker said on Wednesday.
The program aims to protect against the two types of human papillomavirus responsible for about 70 percent of cervical cancers and starts in September for girls aged 12 to 13, the company said.
The decision marks a defeat for Merck's (MRK.N) Gardasil, which competes with the Glaxo drug. (Reporting by Michael Kahn)
- Tweet this
- Share this
- Digg this
- Court orders Russia to pay $50 billion for seizing Yukos assets |
- Israel warns of long Gaza war as Palestinian fighters cross border |
- West agrees wider Russia sanctions as Kiev says forces near crash site |
- Russia, Germany up diplomatic battle over Ukraine sanctions
- Pushing locals aside, Russians take top rebel posts in east Ukraine